Singapore markets close in 1 hour 39 minutes

Straits Times Index
3,336.58
+3.78(+0.11%)
Nikkei
39,631.06
+47.98(+0.12%)
Hang Seng
17,718.61
+2.11(+0.01%)
FTSE 100
8,220.97
+56.85(+0.70%)
Bitcoin USD
63,319.48
+1,671.92(+2.71%)
CMC Crypto 200
1,313.41
+11.33(+0.87%)

HALO Sep 2024 40.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

13.00

0.00

(0.00%)

As of 11:42AM EDT. Market open.

Loading interactive chart…

Zacks
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR Newswire
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.
Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...